Questions about this study?
The HopeStage team will email you.
TerminatedNCT01480232
A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Addiction
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateDecember 2011
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 345
- Sponsor
- A. Eden Evins
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01480232
- Official title
Show the full official title
Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence
Recruitment & locations
TerminatedBoston
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is A. Eden Evins.
Does this study involve medication?
Yes. The study involves medication, including EVP-6124, Placebo Capsule, NicoDerm Patch (Active) and NRT Patch (Placebo).
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me